Artelo Biosciences, Inc.
ARTL
$5.98
-$0.21-3.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.95% | 29.00% | -33.53% | 3.14% | -35.79% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -75.86% | 22.54% | -14.46% | 53.70% | -- |
| Total Other Non-Cash Items | -3.42% | -66.75% | 356.83% | 130.19% | -20.50% |
| Change in Net Operating Assets | -381.49% | 330.33% | 40.99% | -133.16% | 333.74% |
| Cash from Operations | -322.59% | 59.09% | 16.78% | -580.54% | 67.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 175.20% | -- | -- |
| Cash from Investing | -- | -- | 175.20% | -- | -- |
| Total Debt Issued | -100.00% | 559.69% | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.27% | 483.35% | -48.90% | 219.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -109.80% | 575.79% | -53.34% | 89.65% | -- |
| Foreign Exchange rate Adjustments | 450.00% | 200.00% | 90.48% | -333.33% | 260.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -162.80% | 963.66% | -223.70% | -126.21% | 182.91% |